PRAX Dana dhuwit perusahaan Praxis Precision Medicines, Inc.

Praxis Precision Medicines (PRAX) relies on partnerships with universities and pharma behemoths to accelerate development. High R&D expenditures and patent law create a defensive business barrier. The primary focus is directed toward creating molecules for the treatment of epilepsy. The change in cash balance on GURU.Markets reflects liquidity dynamics, where 0.75 expresses the metric value today.
Praxis Medicines (PRAX) - rincian metrik lan laporan keuangan

This metric measures liquid deposits that can generate interest income during periods of tight monetary policy, temporarily masking the core business's operating losses. By analyzing the volume of free cash, a Praxis Precision Medicines (PRAX) investor can determine how long the company can fund the development of epilepsy therapy drugs using reserves before a new equity issuance becomes necessary.